Initial Management of New Onset Atrial Fibrillation with Right Bundle Branch Block

Immediate Assessment and Risk Stratification

The American College of Cardiology recommends assessing for signs of hemodynamic compromise, including hypotension, acute heart failure, chest pain, or altered mental status, to determine the need for emergent direct-current cardioversion in patients with new onset atrial fibrillation and right bundle branch block 2
Obtain 12-lead ECG to confirm atrial fibrillation, document RBBB morphology, and assess for acute ischemic changes, as recommended by the American College of Cardiology 3, 1

The American College of Cardiology recommends initiating beta-blocker therapy as the preferred first-line agent for rate control in hemodynamically stable patients without contraindications 2, 1, 4
Target resting heart rate <100 beats per minute initially, as recommended by the American College of Cardiology 1, 4
Non-dihydropyridine calcium channel blockers are acceptable alternatives in patients without heart failure with reduced ejection fraction, according to the American College of Cardiology 2, 1

Calculate CHA₂DS₂-VASc score immediately to determine stroke risk and anticoagulation necessity, as recommended by the American College of Cardiology 1, 4
Anticoagulation is recommended for all patients except those with truly lone AF and age <60 years, according to the American College of Cardiology 1, 4
Direct oral anticoagulants are preferred over warfarin due to lower intracranial hemorrhage risk and no INR monitoring requirement, as recommended by the American College of Cardiology 1, 4

Transthoracic echocardiography is essential to identify left ventricular dysfunction, valvular disease, left atrial enlargement, and other structural abnormalities, as recommended by the European Society of Cardiology 7, 1, 4
Obtain thyroid function tests to exclude hyperthyroidism as a reversible cause, according to the European Society of Cardiology 7, 1, 4

Elective cardioversion is appropriate for symptomatic patients despite adequate rate control, or those with recent-onset AF (<48 hours), as recommended by the American College of Cardiology 6
Most patients should not receive long-term antiarrhythmic drugs after cardioversion, as risks outweigh benefits, according to the American College of Cardiology 6

Renal function monitoring at least annually when using DOACs, more frequently if baseline impairment, as recommended by the American College of Cardiology 1, 4
Anticoagulation continues indefinitely based on stroke risk factors, regardless of whether sinus rhythm is restored, according to the American College of Cardiology 1, 4